Physiomics plc

With #ProjectOptimus gaining traction, we’re learning that lower doses can be just as effective as higher ones while reducing side effects. This shift makes computer modelling more valuable than ever in getting the dose right first time. An excellent look at why shaking up the ‘maximum tolerated dose’ paradigm is crucial in cancer treatment. 👇 At Physiomics plc, we’re thrilled to contribute to this progress. Our expertise in quantitative and mechanistic modelling helps partners determine the optimal dose and schedule for First-in-Human trials. By aligning with the latest FDA guidelines, we strive to make treatments more personalised and effective. Reach out to learn more! #ProjectOptimus National Cancer Institute (NCI)

Let’s de-risk your drug development journey. At Physiomics plc, our expert team leverages advanced mathematical modelling to predict therapeutic outcomes, helping you navigate R&D challenges across pre-clinical, translational and clinical stages. Learn how our proven solutions can guide your decisions from discovery to the clinic: https://lnkd.in/e7rA8RCH #Cancer #DrugDevelopment #CancerDrugs #CancerSimulation #InSilico #QSP #MathematicalModelling #PKPD #MechanisticModelling #Oncology #ClinicalTrials #ResearchandDevelopment #CancerResearch #BioTech #StatisticalModelling #MachineLearning #Pharma #TranslationalModelling #PYC

A promising step forward in personalised cancer care. Researchers at The Institute of Cancer Research and The University of Manchester have pioneered a new MRI technique that could lead to lower radiotherapy doses for some patients.

💡 The FDA recently finalised new guidance to help drug developers find the right dosage for cancer treatments. To navigate these new requirements, the FDA recommends the use of Model-Informed Drug Development (MIDD) – an area where Physiomics plc has extensive expertise. Our advanced modelling and simulation techniques can help you identify the optimal dosage strategies, minimising risks and maximising the potential for #regulatory and #clinical success. If you’re looking to adapt to these changes and optimise your development process, we’re here to help. Reach out to learn how our tailored solutions can guide you through this new era of oncology drug development! #FDA #DrugDevelopment #Biotech #Pharma #Oncology #OptimalDose #Dosing #Cancer #CancerDrugs #ImprovingOutcomes #MechanisticModelling #ClinicalTrials #Data

At Inaphaea BioLabs, we work with our partner Physiomics plc to provide biological modelling and advanced statistical analysis. Data generated by Inaphaea can be seamlessly integrated into the Physiomics modelling capability for biological modelling and advanced data interpretation. To learn more about how our combined capabilities can enhance your projects, speak to a member of the Inaphaea team: https://bit.ly/3sn67W4 #BioTech #DrugDiscovery #Assays #AssayDevelopment

Learn about our collaboration with Bicycle Therapeutics 🚀 Together, we've developed a PK/PD modelling framework to explore dosing and scheduling for BT7480, a novel, first-in-class Bicycle tumour-targeted immune cell agonist. Check out our poster for more details: https://bit.ly/3Hy8hoV #Pharma #Biotech #DrugDevelopment #PKPD #Innovation

What is Exposure Response Modelling? 🤔 Exposure Response modelling is a key element of PK/PD modelling, helping you connect PK to PD measures like toxicity, biomarker levels, efficacy, or in vitro data. By leveraging all your data, this modelling technique answers critical questions and supports your future development decisions – especially when it comes to justifying human dose predictions and strengthening #regulatory submissions. Curious how Physiomics plc's expertise in exposure response modelling can enhance your drug development process? Let’s talk! https://lnkd.in/eND4sx8s #Biotech #Pharma #DrugDevelopment #PKPD

A look at how scientists are using #AI to fuel drug discovery and bring new treatments to patients, faster 👇 Drug development is a complex and challenging journey. At Physiomics plc, we’re committed to accelerating this process and improving success rates through cutting-edge mathematical modelling techniques. The Breast Cancer Research Foundation

Huge congratulations to our client Servier Pharmaceuticals on the FDA approval of VORANIGO®! 🎉 This is an incredible milestone in precision medicine, especially for those facing the tough battle against brain tumours.

Let’s accelerate your drug development journey. 🚀 Our in silico approaches offer precise predictions and actionable insights that guide your decision-making process from start to finish. Check out how our proven solutions help accelerate and de-risk your R&D efforts: https://lnkd.in/e7rA8RCH #Pharma #Biotech #DrugDevelopment #PKPD #QSP #Pharmacology #Innovation